Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
c-TRAK TN
NCT03145961Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2017
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in triple-negative breast cancer (TNBC) comparing Observation with Pembrolizumab Treatment (2 arms). Primary endpoints: Positive ctDNA detection by 12 months, Positive ctDNA detection by 24 months and 1 more. Status: unknown.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03145961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145961.